About the Webinar: Adverse drug events will cost the Canadian healthcare system about $18 billion in the coming year and cause over 22,000 deaths. The Canadian Network for Advanced Interdisciplinary Methods for comparative effectiveness research (CAN-AIM) responds to drug safety and effectiveness concerns from Health Canada and other regulators. To do so, CAN-AIM depends upon real-world cohort data, including CanPath.
Already, CanPath data have been used by CAN-AIM to study hypertension, diabetes, and other important topics. In this webinar, the CAN-AIM team will illustrate the use of linked drug dispensation records to derive information on the longitudinal use in Canada of H2 blockers, particularly ranitidine, a drug with recently emerging safety concerns.
Register Here
Copyright 2017 - Public Health Physicians of Canada / Médecins de santé publique du Canada
Site by Merge Creative Inc.